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Methods — MSC from C57Bl/6 mice bone marrow were transfected 
with SCF cDNA cloned into pcDNA-3, and a stable transfectant was 
selected in G418 medium. C57Bl/6 mice (N) underwent coronary 
ligation and received medium (M), or 3x105 MSC (C) or MSC 
transfected with SCF (CS) into the anterior left ventricle. Cardiac 
function was assessed by pressure-volume (PV) loops on day 28 
(n=10 per group). Hearts were perfusion- xed in situ and cut into 
transverse sections for computerized planimetry (n=5 per group).
Results — When measured in vivo, myocardial SCF increased 2.9-
fold in M, 5.5-fold in C, and 17.3-fold in SC groups compared to the 
N group (P<0.05). All analysis showed signi cant improvement of 
post MI ventricular size and function in cell groups compared to M 
group. PV loop analysis showed a 1.9-fold increase (P < 0.001) in 
the slope of preload-recruitable stroke work in CS group compared 
with C group. The improvement in end-systolic elastance was 
similar to the improvement in preload-recruitable stroke work. In 
addition, the left ventricular volume was 0.6-fold smaller (P<.01) 
in the CS group compared with the C group. However 4 out of 20 
survivors in CS group developed  brosarcomas in ltrating into the 
cell transplanted area within 3 months of cell implantation.
Conclusions — Use of genetically modi ed MSC over-expressing 
SCF better prevented ventricular dilation and restored cardiac 
function following MI. Unfortunately, this approach was associated 
with tumorogenesis and our data strongly suggests that malignant 
transformation was caused by the speci c combination of 
techniques that we used to generate our cell line.
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Therapeutic angiogenesis is a promising approach to re-establish 
cardiac perfusion following ischemia or in heart failure. Recently, 
it has been proposed that a combination of growth factors may be 
key to the generation of stable vascular networks. However, it is 
currently unknown what growth factor combinations are optimal 
for therapeutic angiogenesis and what mode of administration is 
most adapted to achieve functional revascularization of the heart.
The aim of this study was to investigate the effects of novel growth 
factor combinations and to evaluate their angiogenic effects in 
vivo following delivery with a new biodegradable polymer system.
First, we found that FGF-2 (Fibroblast Growth Factor-2) and HGF 
(Hepatocyte Growth Factor) display synergistic stimulatory effects 
on the migration and proliferation of murine endothelial cells in 
vitro. Furthermore, we show that whereas HGF potentiates the 
proliferative effect of FGF-2 in smooth muscle cells, the HGF-
induced mobility response in these cells is enhanced by FGF-2. 
The molecular mechanisms of the reciprocal stimulatory effects 
involve upregulation in endothelial cells of the HGF receptor, 
c-Met, by FGF-2, and vice versa upregulation of the FGFR-1 by HGF 
stimulation.
Next, we determined the release potential of a new polymeric 
delivery system based on biodegradable alginate microparticules 
adapted for cardiac injection. We found that FGF-2 is liberated 
during less than 1 month with a strong initial level of release during 
the  rst ten days. In contrast, HGF is continuously liberated during 
40 days with a maximal release around day eighth. Our in vivo data, 
from a Matrigel plug assay in mice, indicate a signi cantly increased 
ef cacy of angiogenic therapy using growth factors delivered by 
alginate polymers. Moreover, we found that a combination of HGF 
and FGF-2 displays a potent synergistic angiogenic effect in vivo.
In conclusion, we demonstrate the potential of the speci c 
combination of FGF-2 and HGF in obtaining a synergistic stimulatory 
effect in vitro and in vivo. Further, our new alginate-based 
injectable polymeric system seems well adapted for delivery of 
growth factors for therapeutic angiogenic approaches to ameliorate 
cardiac perfusion
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Bone marrow-derived endothelial progenitor cells (EPCs), present in 
the systemic circulation, are augmented in response to tissue ischemia, 
and incorporate into sites of neovascularization. They possess the 
ability to differentiate into endothelial cells (ECs). Microparticles 
(MPs), small fragments generated from the plasma membrane, are 
able to activate the angiogenic program of ECs through mRNA transfer. 
Also, Peroxisome Proliferator-Activated Receptor (PPAR) alpha agonists 
increase cardiac progenitor differentiation. Here, we have studied the 
effects of circulating MPs obtained from PPARalpha wild type (WT) and 
knock-out (KO) mice on EPC differentiation and in vitro capillary-like 
tube formation of ECs.
MPs were obtained from blood of mice, and MP sub-populations 
were characterized by  ow cytometer. EPCs were isolated from WT 
mice using density gradient separation. Isolated cells were cultured 
in the absence or presence of MPs from PPARalpha WT or KO mice 
for 7 days. Then, expression of speci c markers of EPCs (Sca-1/
Flk-1) were analysed by  ow cytometry or dual binding of FITC-
labeled BS I lectin and Dil-acetylated-LDL by confocal microscopy. 
Also, ECs were isolated from WT mice aorta. The effects of 24 
hours incubation with MPs from PPARalpha WT or KO mice on in 
vitro angiogenesis were assessed by capillary-like tube formation 
assay on Matrigel.
Circulating MPs from PPARalpha mice were mainly derived 
from platelets and leucocytes. MP levels were not signi cantly 
different between strains. Only MPs from PPARalpha WT mice 
harbored PPARalpha. Incubation of EPCs with MPs from PPARalpha 
WT, but not from KO mice, increased signi cantly the number of 
differentiated EPCs. Incubation of ECs with PPARalpha WT-derived 
MPs increased capillary-like tube formation of ECs. By contrast, 
deletion of PPARalpha markedly inhibited in vitro tube formation 
of ECs.
Our results suggest that the presence of PPARalpha in MPs, not 
only stimulates EPCs differentiation, but also favored in vitro 
